The Catechol-o-methyl transferase val158met polymorphism and susceptibility to cannabis dependence

American Journal of Forensic Medicine and Pathology

Volumn 29, Issue 4, 2008, Pages 320-322

  Isir, Aysun Baransel Baransel ^a   Oguzkan, Sibel ^a   Nacak, Muradiye ^b   Gorucu, Senay ^a   Dulger, Hikmet Ergin ^a   Arslan, Ahmet ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b MERSIN UNIVERSITY   (Turkey)

Author keywords

Cannabis; Catechol O methyl transferase; Dopamine; Polymorphism

Indexed keywords

CANNABIS; CATECHOL METHYLTRANSFERASE;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG DEPENDENCE; DRUG USE; EVALUATION; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; CANNABIS ADDICTION; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 65249140612     PISSN: 01957910     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAF.0b013e3181847e56     Document Type: Article

References (28)

1. Lachman HM. An overview of the genetics of substance use disorders. Curr Psychiatry Rep. 2006;8:133-143.
2. Kendler KS, Prescott CA. Cannabis use, abuse, and dependence in a population-based sample of female twins. Am J Psychiatry. 1998;155: 1016-1022.
3. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997;276:2048 -2050.
4. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport. 1997;8:649-652.
5. Gessa GL, Melis M, Muntoni AL, et al. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol. 1998;341:39-44.
6. Wang T, Franke P, Neidt H, et al. Association study of the low-activity allele of catechol-O-methyltransferase and alcoholism using a familybased approach. Mol Psychiatry. 2001;6:109 -111.
7. Lachman HM, Papolos DF, Saito T, et al. Human catechol-O- methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6:243-250.
8. Weinshilboum RM. Human pharmacogenetics of methyl conjugation. Fed Proc. 1984;43:2303-2307.
9. Weinberger DR, Egan MF, Bertolino A, et al. Neurobiology of schizophrenia and the role of atypical antipsychotics: prefrontal neurons and the genetics of schizophrenia. Bio Psychiatry. 2001;50:825-844.
10. Vandenbergh DJ, Rodriguez LA, Miller IT, et al. High-activity catechol- O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet. 1997;74:439-442.
11. Karayiorgou M, Altemus M, Galke BL, et al. Genoypte determining low catechol-O-methyltransferase activity as a risk factor for obsessive compulsive disorder. Proc Natl Acad Sci USA. 1997;94:4572-4575.
12. Lachman HM, Nolan KA, Mohr P, et al. Association between catechol O-methyltransferase genotype and violence in schizophrenia and schizoaffective disorder. Am J Psychiatry. 1998;155:835-837.
13. Kotler M, Barak P, Cohen H, et al. Homicidal behavior in schizophrenia associated with a genetic polymorphism determining low catechol Omethyltransferase (COMT) activity. Am J Med Genet B Neuropsychiatr Genet. 1999;88:628-633.
14. Tiihonen J, Hallikainen T, Lachman H, et al. Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism. Mol Psychiatry. 1999;4:286 -289.
15. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev. 2006;30:215-238.
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: The American Psychiatric Association; 1994.
17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nuc Acid Res. 1988;16: 1215.
18. Erdal E, Tot S, YazIcI K, et al. Lack of association of catechol-Omethyltransferase gene polymorphism in obsessive-compulsive disorder. Depress Anxiety. 2003;18:41-45.
19. Koob G, Nestler E. The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci. 1997;9:482-497.
20. Cevolia S, Mochia M, Scapolib C, et al. A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur J Neurol. 2006;13:1009 -1013.
21. Uhl GR, Vandenbergh DJ, Rodriguez LA, et al. Dopaminergic genes and substance abuse. J Pharmacol Exp Ther. 1998;127:46 -50.
22. Horowitz R, Kotler M, Shufman E, et al. Confirmation of an excess of the high enzyme activity COMTval allele in heroin addicts in a familybased haplotype relative risk study. Am J Med Genet. 2000;96:599-603.
23. Li T, Chen C, Hu X, et al. Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet B Neuropsychiatr Genet. 2004;129B:120 -124.
24. Ishiguro H, Haruo Shibuya T, Toru M, et al. Association study between high and low activity polymorphism of catechol-O-methyltransferase gene and alcoholism. Psychiatr Genet. 1999;9:135-138.
25. Lowinson J, Ruiz P, Millman R, et al. Substance Abuse: A comprehensive Textbook. 3rd ed. Baltimore, MD: Williams & Wilkins; 1997.
26. Bardo MT. Neurophrmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol. 1998;12: 37-67.
27. Akil M, Kolachana BS, Rothmond DA, et al. Catechol-O- methyltransferase genotype and dopamine regulation in the human brain. J Neurosci. 2003;23: 2008-2013.
28. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA. 2001;98:6917-6922.